1.17 USD
▼-0.56-32.17%
盘后 1.20 +2.56%
2026-09-15
市值
$78.09M
市盈率
—
EPS
-1.19
股息率
—
52 周区间
1.06 – 3.82
成交量
11.69M
Beta
-0.18
目标价
7.25
52W 低 1.0652W 高 3.82
价格走势
公司简介
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.